Hong Kong exchange proposes new listing regime to attract tech firms

Updated 2018-02-24 10:21:01 Xinhua

Hong Kong exchange on Friday published a consultation paper seeking public feedback on the proposed new rules to expand Hong Kong's listing regime to attract listings of companies from emerging and innovative sectors.

The public comment period will last for a month and end on March 23, according to the Stock Exchange of Hong Kong Limited (the Exchange), a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited (HKEX).

The proposals in the consultation paper closely follow the way forward as set out by the Exchange on Dec. 15 in 2017 in the New Board Concept Paper Conclusions.

The paper includes draft Main Board Listing Rules to permit listings of biotech issuers that do not meet any of the financial eligibility tests of the Main Board, to permit listings of companies with weighted voting right (WVR) structures, and to establish a new concessionary secondary listing route for companies that wish to secondary list in Hong Kong.

The Exchange has proposed separate new chapters in the Listing Rules for biotech, WVR and the new concessionary secondary listing route.

"In the past few months we have collectively decided to take a big step forward as a financial center and welcome emerging and innovative companies. Now, we are proposing a listing regime that will boost Hong Kong's attractiveness for a new generation of companies as well as investors, bringing more dynamism to our stock market," said HKEX Chief Executive Charles Li.

"Significant momentum has been built for making Hong Kong's capital markets more relevant and even more competitive. We thank all market participants and invite them to help us put the finishing touches on the proposed rule amendments through this latest consultation," Li said.

In its proposals, the Exchange offers specific guidance on the listing eligibility for pre-profit or pre-revenue biotech issuers that produce pharmaceuticals (small molecule drugs), biologics, and medical devices (including diagnostics). Manufacturers of other biotech products will be considered on a case by case basis.

Since issuers listed under the proposed biotech chapter would not meet any of the financial eligibility tests of the Main Board, these issuers potentially carry additional risks to investors.

Accordingly, the proposals include detailed eligibility and suitability criteria for determining appropriate applicants, a higher market capitalization requirement, enhanced disclosure requirements as well as restrictions on fundamental changes of business.

The consultation paper has been posted on the HKEX website.

Also in the News

Nicole Kidman Recalls Oscar Glory: Loneliest Time
Showbiz2016/06/16 13:58January 18 2019 19:12:09

Nicole Kidman Recalls Oscar Glory: Loneliest Time

Attending Shanghai International Film Festival, Nicole Kidman talks about her role in "Grace of Monaco".

Labor Day Travel Peak Starts
Also in the News2014/05/01 12:16January 18 2019 19:12:09

Labor Day Travel Peak Starts

Johnny Depp Delivers a Speech 'Evolve the Future' in 'Transcendence'
Also in the News2014/04/18 13:18January 18 2019 19:12:09

Johnny Depp Delivers a Speech 'Evolve the Future' in 'Transcendence'

Hollywood star Johnny Depp's speech in the upcoming new film "Transcendence" has been disclosed on Friday, April 11th.

China World Business Sports Showbiz Audio
C4 My Chinese Life The Sound Stage China Revealed Showbiz Video Travel Video
China World Fun Travel Entertainment Sports
Beijing Shanghai Guangzhou
Live Music Opera & Classical Movies Traditional Shows Exhibitions
Learn Chinese:
Chinese Studio Living Chinese Everyday Chinese Just For Fun Chinese Culture Buzzwords